Biomarker Research

Table 1 Patient characteristics and treatment outcomes

From: Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

Responders
Patient ID	RECIST at Week 12	Baseline LDH (U/L)	PFS (months)^a	OS (months)^a
G1	PR	167	Response ongoing	Alive
G2	PR	215	Response ongoing	Alive
G3	PR	159	Response ongoing	Alive
G4	PR	217	Response ongoing	Alive
G5	PR	185	Response ongoing	Alive
G6	PR	206	Response ongoing	Alive
G7	PR	268	Response ongoing	Alive
G8	PR	167	Response ongoing	Alive
G9	PR	227	Response ongoing	Alive
G10	PR	187	Response ongoing	Alive
G11	PR	140	Response ongoing	Alive
G12	CR	150	Response ongoing	Alive
Non-responders
Patient ID	RECIST at Week 12	Baseline LDH (U/L)	PFS (months)^a	OS (months)^a
P1	PD	303	2.7	5.8
P2	PD	568	2.7	5.1
P3	PD	329	2.7	3.1
P4	PD	300	1.1	Alive
P5	PD	271	0.5	Alive
P6	PD	267	2.7	Alive
P7	PD	169	2.8	Alive
P8	SD	226	4	Alive
P9	SD	269	4.1	Alive
P10	SD	176	2.7	21.7
P11	SD	195	Response ongoing	Alive
P12	SD	402	5.5	8.3

Abbreviations: PR partial response, SD stable disease, PD progressive disease, CR complete response, LDH lactate dehydrogenase, PFS progression free survival, OS overall survival, U/L units per liter
^aData cut off on 30th April, 2017. 11 out of 24 patients had progressed at time of analysis, all of whom were in the non-responders group. Median follow-up for these patients is 24.3 months. Normal range of LDH is 120–250 U/L

Back to article page

ISSN: 2050-7771

Contact us

General enquiries: journalsubmissions@springernature.com